S1030
Clinical – Sarcoma, skin cancer, malignant melanoma
ESTRO 2026
neutropenia occurred. No other grade 3-5 treatment- related adverse events were reported. Median progression-free survival (PFS) and overall survival (OS) have not yet been reached. Conclusion: The combination of RT, DOXO, and SIN showed potential efficacy and tolerable toxicity in high-risk localized limbs and trunk STS. The trial is still ongoing. Keywords: soft tissue sarcoma, radiotherapy, immunotherapy Outcomes of patients with brain-only metastatic melanoma, treated with stereotactic radiosurgery Charlotte Dawson, Nathaniel L Hatton, Jack Wellington, Keith Howell, Maria Marples, Michael Flatley, Paul Hatfield Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom Purpose/Objective: Metastatic melanoma (MM) spreads to the brain in up to 60% of cases, causing significant mortality.1 Brain Digital Poster 209 metastases (BM) can occur in the absence of detectable MM in other organs. Stereotactic radiosurgery (SRS) offers good local control for a median of 23 months2, but the indications for SRS have changed from the size of the lesions to the number of lesions. This work evaluated outcomes in MM patients with brain-only disease treated with SRS. Material/Methods: This retrospective work identified MM patients with BM treated with SRS from electronic health records between 2013 and 2023. Collected data included patient demographics, symptoms, presence of active extracranial disease, prior melanoma treatments, BRAF mutation status, and clinical outcomes, including overall survival and disease progression. Results: 34 patients were included. 16 patients received systemic therapy (targeted therapies/immunotherapies) before SRS, with 8 having received adjuvant treatment after surgical resection but before SRS, and 8 in the metastatic setting (Table 1). 10 patients underwent multiple SRS treatments. 67.6% had symptoms at the time of SRS. Intracranial progression alone (new metastasis, local recurrence) occurred in 20.6% of patients with an average time to progression of 8 months, 20.6% had extracranial progression alone and 20.6% experienced both intracranial and extracranial progression. The median follow-up period was 21 months.The median overall survival from initial SRS was 21 months (95% CI: 11.8– 30.2). Patients who received systemic therapy before SRS had a median survival of 22 months (95% CI: 12.1–
Proffered Paper 90
A Phase Ib/II Trial of Radiotherapy Combined with Doxorubicin and Sintilimab for Localized High-Risk Limbs and Trunk Soft Tissue Sarcomas Yan WANG 1 , Shujuan ZHOU 1 , Lanyue XU 1 , Yue SU 1 , Yaqi WANG 1 , Ruiyan WU 1 , Lijun SHEN 1 , Juefeng WAN 1 , Yu XU 2 , Yong CHEN 2 , Wangjun YAN 2 , Zhen ZHANG 1 1 Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2 Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China Purpose/Objective: Localized high-risk soft tissue sarcomas (STSs) presents a therapeutic challenge due to limited preoperative treatment options. Radiotherapy (RT) and Doxorubicin (DOXO) are well-established immunogenic cell death inducers, which are capable of boosting the efficacy of immunotherapy even in "cold" tumors. This study aims to evaluate the safety and efficacy of a preoperative triple combination of RT, DOXO, and the PD-1 antibody (SIN) for STS. Material/Methods: In this Phase Ib/II trial (NCT05774275), up to 52 patients will be enrolled. Participants will receive RT (BED=50-60 Gy), combined with DOXO and SIN (200 mg, Day 1) every three weeks for four cycles prior to surgery. In Phase Ib (3+3 design), patients will receive Pegylated liposomal doxorubicin (PLD, 37.5 mg/m ² or 30 mg/m ² , i.v., Day 1) to establish the recommended Phase 2 dose (RP2D). In Phase II, DOXO will be administered as PLD at RP2D or as Doxorubicin Hydrochloride (Adriamycin, ADM, 75 mg/m ² i.v., Day 1). The primary endpoint is the objective response rate (ORR), while secondary endpoints include the rate of pathological complete response (pCR) and near pCR (defined as <10% viable tumor cells), survival, and safety. Results: From September 2022 to February 2025, 35 patients with localized high-risk STSs were enrolled.The median age was 50 years, with 15 (48.4%) males, and 12 (38.7%) patients had prior surgeries. 27 (87.1%) tumors were histological grade 3. No dose-limiting toxicities (DLT) were observed in the first six patients receiving PLD (37.5 mg/m ² , i.v., Day 1, q3w) with SIN, confirming the RP2D. Among the 31 evaluable patients, 2 achieved complete response (CR), 14 achieved partial response (PR), and 13 had stable disease, resulting in an ORR of 51.6% (16/31) and a disease control rate (DCR) of 93.5% (29/31). Among the patients who received surgery, two patients (7.1 %) experienced major wound complications. They underwent secondary operation and readmission to hospital for wound care, respectively. Four grade 3 dermatitis (12.9%) and three (9.7%) grade 3-4
Made with FlippingBook - Share PDF online